Brief: Lyell Immunopharma Announces FDA Clearance Of Its IND For LYL797
16/12/2021 22:34
Dec 16 (Reuters) - Lyell Immunopharma Inc LYEL.O :
* LYELL IMMUNOPHARMA ANNOUNCES FDA CLEARANCE OF ITS IND FOR
LYL797, A CAR T-CELL THERAPY INCORPORATING NOVEL REPROGRAMMING
TECHNOLOGIES FOR SOLID TUMORS
* LYELL IMMUNOPHARMA INC - EXPECTS TO BEGIN SCREENING
PATIENTS FOR
PHASE 1 CLINICAL TRIAL BY END OF Q1; INITIAL DATA PRESENTATION
EXPECTED IN 2023
Source text for Eikon: ID:nGNX1Kcnp3
Further company coverage: LYEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma